FDA Drug Label

What the provider says

Quoted from x402 Bazaar · source record · read 2026-10-26

---

Facts and where they come from

Price

0.003 USDC per call Provider claim

Recorded value: 0.003 USDC per call.

Unit

per call

Protocol

x402, REST · transport: HTTP Provider claim

Auth

x402

Endpoint

https://bess-x402.onrender.com/v1/health/drug-label

Source

x402 Bazaar (Coinbase CDP) · Public discovery API (provider-published records)

Last checked

Not checked by us yet — the data is as the source published it

First seen

2026-10-26

Usage

1 calls · 1 unique payers in the 30 days before 2026-10-26. Measured by the x402 Bazaar, not by us and not by the provider.

Payments and earnings

No settled payment on record. Earnings for this service are unknown — not zero. The source counts 1 calls in 30 days, which at the published price is roughly $0.00 of activity. Activity is not revenue; no charge has been reconciled for it.

Payment rails

A payment rail is where the provider asks to be paid. It is not proof that anything was paid through it. See evidence levels.

Input and output, as published

Request

{
    "method": "GET",
    "queryParams": {
        "limit": 1,
        "name": "metformin"
    },
    "type": "http"
}

Response

{
    "example": {
        "count": 1,
        "labels": [
            {
                "adverse_reactions": "6 ADVERSE REACTIONS The following adverse reactions are also discussed elsewhere in the prescribing information: Lactic Acidosis [see Warnings and Precautions ( 5.1 )] Pancreatitis [see Warnings and Precautions ( 5.2 )] Heart Failure [see Warnings and Precautions ( 5.3 )] Acute Renal Failure [see Wa...",
                "application_number": "NDA216743",
                "boxed_warning": "WARNING: LACTIC ACIDOSIS WARNING: LACTIC ACIDOSIS See full prescribing information for complete boxed warning . Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respirato...",
                "brand_name": "ZITUVIMET",
                "contraindications": "4 CONTRAINDICATIONS Severe renal impairment: (eGFR below 30 mL/min/1.73 m 2 ) ( 4) Metabolic acidosis, including diabetic ketoacidosis. ( 4 ) History of a serious hypersensitivity reaction to ZITUVIMET, sitagliptin, or metformin, such as anaphylaxis or angioedema. (4) ZITUVIMET is contraindicated in...",
                "dosage_and_administration": "2 DOSAGE AND ADMINISTRATION Take ZITUVIMET orally twice daily with meals. ( 2.1 ) Individualize the dosage of ZITUVIMET on the basis of the patient's current regimen, effectiveness, and tolerability. ( 2.1 ) The maximum recommended daily dose is 100 mg of sitagliptin and 2,000 mg of metformin HCl. (...",
                "drug_interactions": "7 DRUG INTERACTIONS Table 4 presents clinically significant drug interactions with ZITUVIMET: Table 4: Clinically Significant Drug Interactions with ZITUVIMET Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-...",
                "generic_name": "SITAGLIPTIN AND METFORMIN HYDROCHLORIDE",
                "indications_and_usage": "1 INDICATIONS AND USAGE ZITUVIMET is a combination of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Z...",
                "label_date": "2026-08-12",
                "manufacturer": "Zydus Lifesciences Limited",
                "ndc": [
                    "70771-1859",
                    "70771-1860"
                ],
                "pharm_class": [
                    "Dipeptidyl Peptidase 4 Inhibitor [EPC]",
                    "Dipeptidyl Peptidase 4 Inhibitors [MoA]"
                ],
                "pregnancy": "8.1 Pregnancy Risk Summary Available data with ZITUVIMET and sitagliptin use in pregnant women are not sufficient to inform a ZITUVIMET-associated or sitagliptin-associated risk for major birth defects and miscarriage. Published studies with metformin use during pregnancy have not reported a clear a...",
                "product_type": "HUMAN PRESCRIPTION DRUG",
                "route": [
                    "ORAL"
                ],
                "rxcui": [
                    "861769",
                    "861819"
                ],
                "set_id": "0098dec4-f0e5-45d5-8aa4-5d0faf9ab142",
                "substances": [
                    "SITAGLIPTIN",
                    "METFORMIN HYDROCHLORIDE"
                ]
            }
        ],
        "note": "Official FDA label text for information only, not medical advice.",
        "query": "metformin",
        "source": "openFDA drug labels (CC0)"
    },
    "type": "json"
}

Examples are the provider's own, not a call we made.

Provenance

One row per statement. “Verified” means we checked it ourselves and the finding is quoted. “Provider claim” means we read it in the provider's own record. “Not found” is a statement about our search, not proof of absence.

Endpoint checks

We have not called this endpoint yet. Until we do, everything above is what the source published — no more.

Tags

---